vs
Pathfinder Bancorp, Inc.（PBHC）与Protalix BioTherapeutics, Inc.（PLX）财务数据对比。点击上方公司名可切换其他公司
Pathfinder Bancorp, Inc.的季度营收约是Protalix BioTherapeutics, Inc.的1.3倍（$11.8M vs $9.1M），Pathfinder Bancorp, Inc.净利率更高（-52.9% vs -60.3%，领先7.4%），Pathfinder Bancorp, Inc.同比增速更快（-22.6% vs -49.9%），Pathfinder Bancorp, Inc.自由现金流更多（$10.4M vs $1.6M），过去两年Pathfinder Bancorp, Inc.的营收复合增速更高（3.0% vs -6.7%）
Pathfinder Bancorp, Inc.是美国区域性银行控股公司，旗下运营探路者银行，服务纽约州中部市场，为个人消费者及中小企业提供存款账户、住房抵押贷款、商业贷款、财富管理等各类金融服务。
Protalix BioTherapeutics是一家以色列制药企业，核心产品为植物源酶制剂他利苷酶阿尔法，该产品已获美国食品药品监督管理局批准，用于治疗戈谢病，专注于开发创新生物技术药物服务患者需求。
PBHC vs PLX — 直观对比
营收规模更大
PBHC
是对方的1.3倍
$9.1M
营收增速更快
PBHC
高出27.3%
-49.9%
净利率更高
PBHC
高出7.4%
-60.3%
自由现金流更多
PBHC
多$8.8M
$1.6M
两年增速更快
PBHC
近两年复合增速
-6.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $11.8M | $9.1M |
| 净利润 | $-5.6M | $-5.5M |
| 毛利率 | — | 49.4% |
| 营业利润率 | -81.1% | -51.1% |
| 净利率 | -52.9% | -60.3% |
| 营收同比 | -22.6% | -49.9% |
| 净利润同比 | -242.4% | -184.8% |
| 每股收益（稀释后） | — | $-0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PBHCPLX
| Q4 25 | $11.8M | $9.1M | ||
| Q3 25 | $13.1M | $17.9M | ||
| Q2 25 | $9.3M | $15.7M | ||
| Q1 25 | $12.6M | $10.1M | ||
| Q4 24 | $15.3M | $18.2M | ||
| Q3 24 | $13.4M | $18.0M | ||
| Q2 24 | $10.7M | $13.5M | ||
| Q1 24 | $11.1M | — |
净利润PBHCPLX
| Q4 25 | $-5.6M | $-5.5M | ||
| Q3 25 | $626.0K | $2.4M | ||
| Q2 25 | $31.0K | $164.0K | ||
| Q1 25 | $3.0M | $-3.6M | ||
| Q4 24 | $3.9M | $6.5M | ||
| Q3 24 | $-4.6M | $3.2M | ||
| Q2 24 | $2.0M | $-2.2M | ||
| Q1 24 | $2.1M | — |
毛利率PBHCPLX
| Q4 25 | — | 49.4% | ||
| Q3 25 | — | 53.4% | ||
| Q2 25 | — | 62.5% | ||
| Q1 25 | — | 19.1% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 53.4% | ||
| Q2 24 | — | 29.8% | ||
| Q1 24 | — | — |
营业利润率PBHCPLX
| Q4 25 | -81.1% | -51.1% | ||
| Q3 25 | 5.1% | 11.9% | ||
| Q2 25 | 0.4% | 7.5% | ||
| Q1 25 | 29.5% | -41.0% | ||
| Q4 24 | 55.4% | 39.6% | ||
| Q3 24 | -43.1% | 22.2% | ||
| Q2 24 | 23.3% | -18.0% | ||
| Q1 24 | 24.3% | — |
净利率PBHCPLX
| Q4 25 | -52.9% | -60.3% | ||
| Q3 25 | 4.8% | 13.2% | ||
| Q2 25 | 0.3% | 1.0% | ||
| Q1 25 | 23.6% | -35.8% | ||
| Q4 24 | 37.7% | 35.6% | ||
| Q3 24 | -34.6% | 18.0% | ||
| Q2 24 | 18.7% | -16.4% | ||
| Q1 24 | 19.0% | — |
每股收益（稀释后）PBHCPLX
| Q4 25 | — | $-0.06 | ||
| Q3 25 | $0.47 | $0.03 | ||
| Q2 25 | $0.47 | $0.00 | ||
| Q1 25 | — | $-0.05 | ||
| Q4 24 | — | $0.10 | ||
| Q3 24 | $0.41 | $0.03 | ||
| Q2 24 | $0.41 | $-0.03 | ||
| Q1 24 | — | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $14.7M |
| 总债务越低越好 | $14.1M | — |
| 股东权益账面价值 | $122.5M | $48.2M |
| 总资产 | $1.4B | $82.3M |
| 负债/权益比越低杠杆越低 | 0.11× | — |
8季度趋势，按日历期对齐
现金及短期投资PBHCPLX
| Q4 25 | — | $14.7M | ||
| Q3 25 | — | $13.6M | ||
| Q2 25 | — | $17.9M | ||
| Q1 25 | — | $19.5M | ||
| Q4 24 | — | $19.8M | ||
| Q3 24 | — | $27.4M | ||
| Q2 24 | — | $23.4M | ||
| Q1 24 | — | — |
总债务PBHCPLX
| Q4 25 | $14.1M | — | ||
| Q3 25 | $18.7M | — | ||
| Q2 25 | $21.0M | — | ||
| Q1 25 | $17.6M | — | ||
| Q4 24 | $27.1M | — | ||
| Q3 24 | $39.8M | — | ||
| Q2 24 | $45.9M | — | ||
| Q1 24 | $45.9M | — |
股东权益PBHCPLX
| Q4 25 | $122.5M | $48.2M | ||
| Q3 25 | $126.3M | $52.9M | ||
| Q2 25 | $124.4M | $49.9M | ||
| Q1 25 | $124.9M | $45.2M | ||
| Q4 24 | $121.5M | $43.2M | ||
| Q3 24 | $120.2M | $32.4M | ||
| Q2 24 | $123.3M | $28.6M | ||
| Q1 24 | $121.8M | — |
总资产PBHCPLX
| Q4 25 | $1.4B | $82.3M | ||
| Q3 25 | $1.5B | $82.3M | ||
| Q2 25 | $1.5B | $78.5M | ||
| Q1 25 | $1.5B | $73.9M | ||
| Q4 24 | $1.5B | $73.4M | ||
| Q3 24 | $1.5B | $61.6M | ||
| Q2 24 | $1.4B | $91.5M | ||
| Q1 24 | $1.5B | — |
负债/权益比PBHCPLX
| Q4 25 | 0.11× | — | ||
| Q3 25 | 0.15× | — | ||
| Q2 25 | 0.17× | — | ||
| Q1 25 | 0.14× | — | ||
| Q4 24 | 0.22× | — | ||
| Q3 24 | 0.33× | — | ||
| Q2 24 | 0.37× | — | ||
| Q1 24 | 0.38× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $11.7M | $2.0M |
| 自由现金流经营现金流 - 资本支出 | $10.4M | $1.6M |
| 自由现金流率自由现金流/营收 | 88.1% | 17.8% |
| 资本支出强度资本支出/营收 | 10.7% | 4.4% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $18.4M | $-13.6M |
8季度趋势，按日历期对齐
经营现金流PBHCPLX
| Q4 25 | $11.7M | $2.0M | ||
| Q3 25 | $7.0M | $-3.7M | ||
| Q2 25 | $-3.7M | $-5.2M | ||
| Q1 25 | $5.7M | $-5.1M | ||
| Q4 24 | $11.2M | $4.0M | ||
| Q3 24 | $11.8M | $4.1M | ||
| Q2 24 | $1.5M | $-3.6M | ||
| Q1 24 | $504.0K | — |
自由现金流PBHCPLX
| Q4 25 | $10.4M | $1.6M | ||
| Q3 25 | $6.9M | $-4.2M | ||
| Q2 25 | $-4.0M | $-5.7M | ||
| Q1 25 | $5.1M | $-5.4M | ||
| Q4 24 | $9.1M | $3.6M | ||
| Q3 24 | $11.3M | $4.0M | ||
| Q2 24 | $637.0K | $-3.8M | ||
| Q1 24 | $274.0K | — |
自由现金流率PBHCPLX
| Q4 25 | 88.1% | 17.8% | ||
| Q3 25 | 52.8% | -23.7% | ||
| Q2 25 | -42.6% | -36.2% | ||
| Q1 25 | 40.1% | -53.0% | ||
| Q4 24 | 59.9% | 19.6% | ||
| Q3 24 | 84.3% | 22.4% | ||
| Q2 24 | 6.0% | -28.1% | ||
| Q1 24 | 2.5% | — |
资本支出强度PBHCPLX
| Q4 25 | 10.7% | 4.4% | ||
| Q3 25 | 1.0% | 2.8% | ||
| Q2 25 | 2.4% | 2.8% | ||
| Q1 25 | 5.1% | 3.0% | ||
| Q4 24 | 13.5% | 2.3% | ||
| Q3 24 | 3.8% | 0.5% | ||
| Q2 24 | 8.2% | 1.3% | ||
| Q1 24 | 2.1% | — |
现金转化率PBHCPLX
| Q4 25 | — | — | ||
| Q3 25 | 11.26× | -1.58× | ||
| Q2 25 | -120.55× | -31.91× | ||
| Q1 25 | 1.92× | — | ||
| Q4 24 | 2.87× | 0.61× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | 0.76× | — | ||
| Q1 24 | 0.24× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PBHC
| Other | $5.6M | 47% |
| Banking | $3.7M | 31% |
| Deposit Account | $1.5M | 13% |
| Financial Service Other | $1.0M | 9% |
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
